Scientific deep-dive
Does Anthem Cover Zepbound for Weight Loss? Honest Evidence Review
Yes on Anthem commercial plans that include weight-loss drugs, with PA (BMI ≥30, or ≥27 + a weight-related condition, plus a six-month supervised program unless an exception applies). Self-funded plans may exclude weight-loss drugs. Medicare covers Zepbound only for sleep apnea.
Short version: Anthem's commercial drug lists carry Zepbound with prior authorization, but only plans that include weight-loss drugs pay for it. On those plans, Anthem's Zepbound criteria (revised September 16, 2026) ask for a BMI of 30 or higher, or 27 or higher with a weight-related condition, plus six months in a provider-supervised diet and exercise program. That six-month requirement is waived for a BMI of 40 or higher, advanced heart failure, or moderate-to-severe sleep apnea, and the criteria do not make you try Wegovy first. Anthem Medicare Advantage cannot cover Zepbound for weight loss alone because of the federal Part D exclusion, but Part D can cover it for the FDA-approved sleep apnea indication. Self-funded employer plans can leave weight-loss drugs out entirely, which is the employer's call, not Anthem's. Below we cite Anthem's criteria and drug list, the federal exclusion statute, and the FDA label behind the sleep-apnea pathway.
The honest answer
Yes, with conditions, if your Anthem commercial plan includes weight-loss drugs: prior authorization, BMI ≥30 (or ≥27 with a weight-related condition), and six months in a supervised diet and exercise program unless an exception applies. First approvals last 36 weeks, and renewals need 5% weight loss. Anthem Medicare Advantage can cover Zepbound for sleep apnea through Part D, not for weight loss. Self-funded employer plans may exclude weight-loss drugs entirely. Always verify with your specific plan and group number. An earlier version of this page cited Anthem document CC-0188, which is Anthem's criteria for a different drug (Imcivree); we now cite Anthem's Zepbound criteria.
At a glance
- Anthem commercial: YES with prior authorization if your plan includes weight-loss drugs. Zepbound is Tier 2 with prior authorization, a one-pen-a-week limit and a benefit-exclusion flag on the Virginia National Drug List, and it moved to Tier 3 on Anthem's California lists on January 1, 2026.[12][13]
- Anthem self-funded employer (ASO): depends entirely on the employer. Many employers exclude weight-loss drug coverage even when the Anthem commercial formulary includes Zepbound. Ask HR or Benefits.
- Anthem Medicare Advantage: NO for weight-loss-only Zepbound — federal Part D excludes agents “when used for the symptomatic relief of cough and colds, anorexia, weight loss, or weight gain.” [5] Part D can cover the separate FDA-approved moderate-to-severe obstructive sleep apnea indication (approved December 20, 2024), depending on your plan's formulary.[4][6]
- Anthem Medicaid: varies by state. Virginia (Anthem HealthKeepers Plus) requires BMI >40, or >37 with dyslipidemia, hypertension or type 2 diabetes.[3] California Medi-Cal removed weight-loss GLP-1 coverage effective January 1, 2026.[2]
- PA criteria: age 18+; BMI ≥30, or ≥27 with high blood pressure, type 2 diabetes, dyslipidemia, sleep apnea or cardiovascular disease, documented within 90 days; and six months in a supervised diet and exercise program with under 5% loss, which is waived at BMI ≥40, class III or IV heart failure, or AHI ≥15. [1]
- Step therapy: none. Anthem's Zepbound criteria do not require trying Wegovy first, and Zepbound and Wegovy share Tier 2 on the Virginia National Drug List.[1][12]
- Medicare GLP-1 Bridge (July 1, 2026 to December 31, 2027): eligible Part D enrollees can get Zepbound for weight management with a $50 copay, but only the Zepbound KwikPen formulation, not vials or single-dose pens. CMS decides eligibility from BMI and conditions such as prediabetes or a prior heart attack or stroke; people with type 2 diabetes, sleep apnea or MASH use regular Part D instead.[7][14][15]
Anthem commercial plans: covered with PA when weight-loss drugs are included
Anthem's Zepbound clinical criteria (revised September 16, 2026 and approved by the CarelonRx Pharmacy and Therapeutics Committee) are linked from each Zepbound entry in Anthem's commercial drug-list search.[1] The adult criteria:
- Age 18 or older.
- BMI ≥ 30 kg/m², OR BMI ≥ 27 kg/m² with at least one of these: high blood pressure (treated, or 130/80 or above), type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease. The BMI must be documented within 90 days.
- Six months in a provider-supervised program before the request: a calorie target about 500 kcal a day below your needs, 150 minutes of exercise a week unless you are clinically limited, and less than 5% weight loss. This is waived for BMI ≥ 40, NYHA class III or IV heart failure, or moderate-to-severe sleep apnea (AHI ≥ 15). You also have to stay in a supervised program during treatment.
- First approval lasts 36 weeks. Renewals last one year and need documented 5% weight loss, achieved or maintained, recorded within 90 days of each renewal.
- Not approved with a BMI under 18.5, a history of medullary thyroid carcinoma or MEN 2, or alongside another GLP-1 or tirzepatide product.
Out-of-pocket once PA is approved: your cost depends on your plan's tier and benefit design. Zepbound is Tier 2 on the Virginia National Drug List and Tier 3 on Anthem's California lists. The Lilly Zepbound Savings Card can lower the cost for eligible patients with commercial coverage, so check Lilly's current terms.
Anthem self-funded employer (ASO) plans — employer decides
This is the single biggest source of confusion. A large fraction of Anthem-branded plans are self-funded (also called “ASO” — Administrative Services Only). The employer pays claims directly from a corporate health trust; Anthem just rents out its provider network, claims-processing infrastructure, and pharmacy benefit manager (CarelonRx). On these plans the employer chooses whether to cover weight-loss drugs at all.
Even if Anthem's commercial formulary lists Zepbound as covered with PA, your specific self-funded employer can carve out anti-obesity medications as a non-covered benefit class — and many do, citing the cost. KFF and Mercer employer-survey data through 2025 showed roughly half of large self-funded employers excluded GLP-1 weight-loss agents from their benefits design.
How to tell if your Anthem plan is self-funded: ask HR or look at your Summary Plan Description (SPD) — it will say “self-insured” or “fully insured” somewhere in the plan-administration section. The SPD for a self-funded plan also typically lists the employer (not Anthem) as the “Plan Sponsor.” If self-funded, your appeals path goes through ERISA (federal law) and your employer's plan administrator — not through Anthem's state-insurance external review.
Anthem Medicare Advantage — NO for weight loss, YES for sleep apnea
Anthem Medicare Advantage plans operate under federal Medicare Part D rules. Social Security Act §1860D-2(e)(2)(A) explicitly excludes “agents when used for anorexia, weight loss, or weight gain” from Part D coverage.[5] This statutory exclusion is why no Medicare plan — Anthem MA-PD or otherwise — covers Zepbound for weight-loss-only indications today.
The sleep-apnea exception: on December 20, 2024, the FDA approved Zepbound as the first medication ever approved for moderate-to-severe obstructive sleep apnea in adults with obesity.[6] The Zepbound DailyMed label (SetID 487cd7e7-434c-4925-99fa-aa80b1cc776b, label updated 04/22/2026) lists the second indication verbatim as: “to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity.” [4] Because OSA is a distinct FDA-approved indication — not weight loss — the §1860D-2(e)(2)(A) Part D exclusion does NOT apply, and Anthem MA-PD plans can cover Zepbound for OSA subject to PA. The SURMOUNT-OSA trial (Malhotra et al., NEJM 2024, PMID 38912654) is the underlying evidence base.[10] For the full clinical picture, see our SURMOUNT-OSA tirzepatide / sleep apnea evidence article.
The Medicare GLP-1 Bridge (July 1, 2026 onward): a separate, time-limited federal program covers Wegovy (injection or tablet), Zepbound KwikPen only and Foundayo for weight management with a $50 copay through December 31, 2027. Anthem's provider notice says the patient must be 18 or older and must not have type 2 diabetes, moderate-to-severe sleep apnea or MASH, and that CMS decides final eligibility. The CMS request form asks for BMI at the start of therapy plus conditions such as prediabetes, a prior heart attack or stroke, peripheral artery disease, heart failure with preserved ejection fraction, uncontrolled high blood pressure, or chronic kidney disease. Because the Bridge runs outside the Part D benefit, CMS says the Part D deductible does not apply, none of the $50 copay counts toward your Part D out-of-pocket total, and Extra Help does not reduce it. [7][14][15]
Anthem Medicaid: state by state
Anthem runs Medicaid managed-care plans under state-specific names, such as Anthem HealthKeepers Plus in Virginia. Each state's Medicaid rules and Preferred Drug List apply, not Anthem's commercial criteria. Two examples:
- Virginia (Anthem HealthKeepers Plus): the September 2026 Weight Loss Management PA Form requires BMI > 40 kg/m², or > 37 kg/m² with dyslipidemia, hypertension or type 2 diabetes, plus a failed non-GLP-1 weight-loss drug. Approvals last six months, and renewals need at least 5% weight loss since the last approval.[3]
- California (Anthem Blue Cross Medi-Cal): under the November 14, 2025 notice, Wegovy, Zepbound and Saxenda left the Medi-Cal Rx drug list on January 1, 2026. Requests are still considered for Zepbound for obstructive sleep apnea and for Wegovy for MASH or cardiovascular disease, but weight-loss-only Zepbound is no longer covered.[2]
For an exhaustive state breakdown and the Medicare/commercial/ FEHB/Tricare/VA landscape, see our GLP-1 insurance coverage landscape article.
Step therapy: no Wegovy-first rule in Anthem's criteria
None of Anthem's published criteria requires you to try Wegovy before Zepbound. On the Virginia National Drug List (current as of October 1, 2026), Wegovy and Zepbound sit on the same tier with prior authorization, quantity limits and a benefit-exclusion flag, and neither has a step-therapy flag. California goes the other way: since January 1, 2026, Wegovy has been non-formulary on Anthem's California commercial lists while Zepbound is Tier 3.[1][12][13] If your own plan's drug list does show a step-therapy flag for Zepbound, Anthem has a step-therapy exception request, and the records below can support it.
If your plan does apply a step, these records tend to support an exception:
- Less than 5% weight loss after a documented Wegovy trial at the maintenance dose.
- Persistent intolerable adverse effects on Wegovy that did not resolve with dose adjustment (severe nausea, vomiting, injection-site reactions).
- A contraindication to semaglutide that does not apply to tirzepatide (rare — both share the personal/family history of medullary thyroid carcinoma and MEN-2 boxed warnings).
For the operational detail, including Anthem's full Wegovy, Zepbound, Saxenda and Foundayo criteria, how CarelonRx and the drug lists fit together, and the appeal pathway, see our Anthem GLP-1 prior-authorization guide (the operational companion to this coverage answer). If your card says Blue Cross Blue Shield but you live outside Anthem's 14 states, a different Blue company sets the rules, and weight-loss coverage across those other Blues varies plan by plan.
Magnitude comparison
Typical monthly out-of-pocket cost for Zepbound by Anthem pathway. Commercial PA-approved with savings card is the cheapest brand option; cash-pay retail (no PA, no card) is the most expensive. Compounded tirzepatide via verified 503A telehealth is the cheapest path overall but is not brand Zepbound.[1][7][11]
- Anthem commercial — PA approved + savings card25 $/molowest brand path
- Anthem commercial — PA approved, no card75 $/mo
- Anthem MA-PD — sleep apnea indication100 $/moOSA only; not weight loss
- Medicare GLP-1 Bridge (July 1, 2026)50 $/moKwikPen only; bridge eligible
- LillyDirect Self Pay vial — 2.5 mg starting dose299 $/mo
- LillyDirect Self Pay vial — 7.5 mg therapeutic499 $/mo
- LillyDirect Self Pay vial — 10/12.5/15 mg699 $/mo
- Anthem denied — retail brand cash-pay (autoinjector)1,300 $/moworst case
- Compounded tirzepatide — 503A telehealth250 $/monot brand Zepbound
What to do if Anthem denies your Zepbound PA
The Anthem appeals process gives commercial members 180 days from the denial notice to file a written internal appeal. The sequence:
- Get the written denial letter. It will name the specific clause your submission failed (BMI threshold, missing lifestyle-program documentation, step therapy not satisfied, formulary tier exception not requested, etc.).
- Identify the actual problem. Common causes are a plan that excludes weight-loss drugs, missing documentation of the six-month lifestyle program, or BMI and weight records older than 90 days.
- File an internal appeal with a Letter of Medical Necessity. Include baseline BMI, comorbidity documentation (HTN, T2D, dyslipidemia, or OSA diagnosis), the dated lifestyle-program records, and, if you qualify for an exception to the six-month program, documentation of BMI ≥40, class III or IV heart failure, or moderate-to-severe sleep apnea.
- If the internal appeal is denied, request an external review through Anthem's independent review organization (commercial fully-insured plans) OR through your state insurance department (some states require routing through them). External-review decisions are binding on commercial plans. For ERISA self-funded plans, the appeal goes through your employer's plan administrator and the U.S. Department of Labor — not Anthem.
Switching from Wegovy to Zepbound on Anthem
If you started on Wegovy under Anthem coverage and want to switch, Anthem's criteria do not require Wegovy to have failed. Your prescriber submits a Zepbound request under the Zepbound criteria:
- If you are already on a GLP-1, the request is reviewed against the same criteria, so your starting BMI and the weight loss documented so far both matter.
- Stop Wegovy when Zepbound starts, because Anthem will not approve two GLP-1 drugs at the same time.
- For the dose-equivalence picture (Wegovy 2.4 mg ≈ Zepbound 5-10 mg starting territory), see our Wegovy → Zepbound switch dose-equivalence guide.
If Anthem denies — alternatives that actually work
While the appeal is in flight, the practical alternatives ranked by cost:
- Compounded tirzepatide via verified 503A telehealth — typical $149-$349/month. Not brand Zepbound (the active pharmaceutical ingredient is the same, but quality and supply-chain rigor vary widely across compounding pharmacies). See our where-to-buy tirzepatide guide for the verified-provider directory.
- LillyDirect Self Pay Pharmacy single-dose vials — $299/month (2.5 mg) → $399 (5 mg) → $499 (7.5 mg) → $699 (10/12.5/15 mg) as of the December 1, 2025 price reduction. The Zepbound self-pay program at $449/month is available to eligible patients on the 7.5 mg dose and above.[11]
- Retail-pharmacy brand Zepbound autoinjector — list price typically $1,000-$1,300/month depending on dose. Avoid this path unless absolutely necessary; LillyDirect vials at the same effective dose are roughly half the cost.
- Wait for Medicare GLP-1 Bridge (July 1, 2026) — for eligible Part D enrollees without type 2 diabetes, sleep apnea or MASH, with CMS deciding eligibility. $50 copay through December 31, 2027. Zepbound KwikPen only; vials and single-dose pens are NOT in the bridge.[7]
For mechanism-of-action context (SURMOUNT-1 demonstrated ~20.9% body-weight reduction at 72 weeks on tirzepatide 15 mg[8]; SURMOUNT-2 confirmed efficacy in T2D +obesity[9]), see our tirzepatide vs semaglutide head-to-head article.
Verdict — what most Anthem members should expect
For most Anthem-insured patients asking does Anthem cover Zepbound for weight loss: yes, if your commercial plan includes weight-loss drugs, with prior authorization, a BMI ≥30 (or ≥27 with a weight-related condition), and six months in a supervised program unless an exception applies. What you pay depends on your plan's tier.
The exceptions are the load-bearing details — verify all three before committing to a treatment plan:
- Is your plan self-funded? If yes, ask HR whether weight-loss medications are a covered benefit class. Anthem's commercial formulary tells you nothing if your employer carved them out.
- Are you on Anthem Medicare Advantage? If yes, weight-loss-only Zepbound is NOT covered today. Since December 20, 2024, Part D can cover sleep-apnea Zepbound if you have moderate-to-severe OSA, depending on your plan. The Medicare GLP-1 Bridge (July 1, 2026 to December 31, 2027) opens a third path.
- Are you on Anthem Medicaid? Your state's Medicaid rules apply, not Anthem's commercial criteria. California Medi-Cal removed weight-loss GLP-1 coverage effective January 1, 2026; Virginia HealthKeepers Plus requires BMI > 40, or > 37 with a listed risk factor. Check your state.
For the side-effect picture once coverage is sorted, see our GLP-1 side-effect questions hub — the most-asked questions from active GLP-1 users with primary-source answers. For drug-specific reference data, see the Zepbound drug page and the tirzepatide active-ingredient page.
Disclaimer
This article is informational and does not constitute medical, financial, or legal advice. Insurance coverage decisions are made by your specific plan and employer, not by the criteria document Anthem publishes. Always verify coverage with the member-services number on the back of your insurance card and the group number on your benefits documents before committing to a treatment plan or paying out-of-pocket for a denial that may be appealable. Quoted PA criteria, BMI thresholds, and copays are sourced to the primary-source documents cited below and were current as of July 2026; payer policies change frequently.
Further reading
- Top GLP-1 insurance-coverage questions on Reddit, answered
- Top tirzepatide weight-loss studies (curated PubMed reading list)
- GLP-1 contraindications cheat sheet
Key terms, explained
New to GLP-1s? Tap any term for a quick, plain-English definition.
- Zepbound · Drugs and brands
- Tirzepatide · Drugs and brands
- Wegovy · Drugs and brands
- Semaglutide · Drugs and brands
- Prior authorization (PA) · Insurance and regulatory
- Step therapy · Insurance and regulatory
- Compounded GLP-1 · Pharmacy and drug forms
Our reviews
Providers that offer tirzepatide
Telehealth providers we’ve reviewed. Each opens our full, independent review.
Featured partners
Partners · our scores never change
- Editorial score: 7.3. Read our review of HealthRXFlat-price compounded GLP-1, LegitScript-certified cash-pay programFrom$214/moafter intro offercompounded
- Editorial score: 7.3. Read our review of MEDGmBrand Wegovy, Zepbound or Ozempic access alongside cheaper compounded GLP-1From$399/moafter intro offercompounded
- Editorial score: 7.2. Read our review of EdenCompounded semaglutide or tirzepatide at one flat monthly price that doesn't rise with your doseFrom$129/mocompounded
- Editorial score: 7.2. Read our review of HumeCare+GLP-1 weight loss with real-time body-composition tracking to protect muscleFrom$299/mocompounded
- Editorial score: 7.2. Read our review of LttlEvery commitment tier priced openly, plus a low-dose microdose optionFrom$149/4 wksbilled per 4 weekscompounded
We may earn a commission from featured partners. Learn more
See the full ranking →Frequently Asked Questions
References
- 1.Anthem Blue Cross and Blue Shield; CarelonRx Pharmacy and Therapeutics Committee. Zepbound (tirzepatide) clinical criteria: chronic weight management. Revised September 16, 2026. Linked as Clinical Criteria from Anthem's commercial drug-list search (anthem.com/pharmacy-information). 2026. https://fm.formularynavigator.com/FormularyNavigator/DocumentManager/Download?clientDocumentId=uQnefMVvOkyWWxbLFQEp8w
- 2.Anthem Blue Cross (California). GLP-1 Coverage Considerations (Medi-Cal), November 14, 2025. Wegovy, Zepbound and Saxenda removed from the Medi-Cal Rx Contract Drugs List effective January 1, 2026; PA still considered for Wegovy (MASH or cardiovascular disease) and Zepbound (OSA). providers.anthem.com/docs/gpp/california-provider/CA_MMP_GLP1Coverage.pdf. 2025. https://providers.anthem.com/docs/gpp/california-provider/CA_MMP_GLP1Coverage.pdf
- 3.Anthem HealthKeepers Plus (Virginia Medicaid). Weight Loss Management Prior Authorization Form (September 2026, VA-BCBS-CD-019947-26). GLP-1 criteria: BMI >40, or >37 with dyslipidemia, hypertension or type 2 diabetes; failed non-GLP-1 weight-loss drug; 6-month approvals. providers.anthem.com/docs/gpp/VA_CAID_WeightLossMgmtPAForm.pdf. 2026. https://providers.anthem.com/docs/gpp/VA_CAID_WeightLossMgmtPAForm.pdf
- 4.Eli Lilly. Zepbound (tirzepatide) injection — Highlights of Prescribing Information. Indications: chronic weight management; moderate-to-severe obstructive sleep apnea in adults with obesity. dailymed.nlm.nih.gov SetID 487cd7e7-434c-4925-99fa-aa80b1cc776b (label updated 04/22/2026). 2026.
- 5.Centers for Medicare & Medicaid Services (CMS). Social Security Act §1860D-2(e)(2)(A) — Part D excluded drugs (agents when used for weight loss). ssa.gov/OP_Home/ssact/title18/1860D-2.htm. 2024.
- 6.U.S. Food and Drug Administration. FDA approves first medication for obstructive sleep apnea (Zepbound expanded indication, 12/20/2024). fda.gov news release 12/20/2024. 2024.
- 7.Centers for Medicare & Medicaid Services (CMS). Medicare GLP-1 Bridge: time-limited coverage of Wegovy, Zepbound KwikPen and Foundayo, July 1, 2026 through December 31, 2027. FAQ: $50 copay; Part D deductible does not apply; copay does not count toward TrOOP. cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge. 2026. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge
- 8.Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, et al.; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022. PMID: 35658024.
- 9.Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, et al.; SURMOUNT-2 Investigators. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023. PMID: 37385275.
- 10.Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, et al.; SURMOUNT-OSA Investigators. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024. PMID: 38912654.
- 11.Eli Lilly. LillyDirect Self Pay Pharmacy — Zepbound single-dose vial cash-pay tiers (effective 12/01/2025): 2.5 mg $299, 5 mg $399, 7.5 mg $499, 10/12.5/15 mg $699. Zepbound self-pay program: $449 (7.5 mg and above) for eligible patients. lillydirect.lilly.com pricing snapshot. 2026.
- 12.Anthem Blue Cross and Blue Shield. Virginia National Drug List, 3 Tier (current as of October 1, 2026). Zepbound Tier 2 with PA, BE and QL (1 pen per week). fm.formularynavigator.com (linked from anthem.com/pharmacy-information). 2026. https://fm.formularynavigator.com/FBO/143/National_3_Tier_ABCBSVa.pdf
- 13.Anthem Blue Cross and Blue Shield. January formulary deletions (Commercial). Published March 1, 2026, effective January 1, 2026. Anthem Provider News. 2026. https://providernews.anthem.com/virginia/articles/january-formulary-deletions-28766
- 14.Anthem Blue Cross and Blue Shield. Prepare prescriptions for the Medicare Bridge program (Medicare Advantage). September 24, 2026. Anthem Provider News. 2026. https://providernews.anthem.com/virginia/articles/prepare-prescriptions-for-the-medicare-bridge-program-32351
- 15.Centers for Medicare & Medicaid Services (CMS). Medicare GLP-1 Bridge Prior Authorization Request Form. cms.gov. 2026. https://www.cms.gov/files/document/glp-1-bridge.pdf
Related research
Anthem GLP-1 Prior Authorization Guide: Wegovy, Zepbound, Saxenda and Foundayo Criteria
Anthem's current commercial PA criteria for Wegovy, Zepbound, Saxenda and Foundayo, from the CarelonRx-approved documents on Anthem's drug lists, plus Virginia Medicaid, California Medi-Cal and Medicare Bridge rules and how Anthem compares with Aetna and Cigna.
14 min read
Does Blue Cross Blue Shield Cover Weight Loss Drugs? Honest Coverage Review
Blue Cross Blue Shield is ~33 independent companies plus the FEP, with no single formulary. T2D GLP-1s are widely covered with PA; weight-loss GLP-1s vary by plan, and some Blues dropped them in 2025–2026. Medicare members may use the $50 GLP-1 Bridge.
12 min read
Does Aetna Cover GLP-1 Weight Loss Drugs? Honest Coverage Review
Aetna's pharmacy benefit is run by CVS Caremark. T2D GLP-1s are covered with PA; Wegovy, Zepbound and Foundayo for weight loss only if your employer added the AOM benefit. Zepbound returned to Caremark formularies 10/1/2026; Medicare members may qualify for the $50 GLP-1 Bridge.
11 min read
Does Humana Cover Weight Loss Drugs? Honest Coverage Review
Humana is mainly a Medicare insurer, so federal Part D law excludes weight-loss-only Wegovy, Zepbound, and Saxenda. T2D GLP-1s, Zepbound for sleep apnea, and Wegovy for heart risk or MASH are coverable with PA. The CMS GLP-1 Bridge offers $50/month since July 2026.
11 min read
Does Kaiser Permanente Cover Weight Loss Drugs? Honest Coverage Review
It depends on your region and plan tier. Kaiser covers type 2 diabetes GLP-1s with internal prior authorization, but weight-management coverage of Wegovy, Zepbound and Saxenda varies, and large employers often exclude it. KP Medi-Cal in California dropped them Jan 1, 2026.
11 min read
Does UnitedHealthcare Cover Weight Loss Drugs? OptumRx Coverage Review
UnitedHealthcare covers type 2 diabetes GLP-1s (Ozempic, Mounjaro, Trulicity, Rybelsus) with prior authorization, but excludes weight-loss drugs under most plans unless the employer opts in. Medicare members may qualify for the $50 Medicare GLP-1 Bridge.
12 min read
Where to get tirzepatide (Mounjaro / Zepbound) safely: vetted online providers
Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.
No insurance needed · vetted by our editors
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money
From $129/mo (sale price)
Get started →Gala
Compounded semaglutide or tirzepatide at one all-doses price on a yearly plan, with free shipping
Read full review →From $179/mo (prepaid plan rate)
Get started →Found
Medication-included compounded GLP-1 from $169/mo on a 12-month prepaid plan, plus brand insurance help
Read full review →From $239/mo (12-month plan rate)
Get started →